IP Library Granted Patent US 10,226,506
Granted Patent B2
US 10,226,506 · App. 15/833,544 · Granted Mar 12, 2019

Treatment and diagnosis of inflammatory disorders and HIV

Inventors: Scott C. Kachlany (Bridgewater, NJ); Benjamin Belinka (Kendall Park, NJ)
Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY; ACTINOBAC BIOMED, INC.
A61K38/164A61K39/3955A61K45/06A61K47/6849A61K51/1093C07K16/2896G01N33/5052G01N33/56911A61K2039/505C07K2317/24G01N33/56988G01N2800/26G01N2800/52G01N2800/709G01N2800/7095Y10S530/825
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,226,506
App. No.
15/833,544
Granted
Mar 12, 2019
Kind
B2
Abstract

This invention concerns compositions and methods of treating or diagnosing inflammatory disorders and other disorders, as well as compositions and methods of treating HIV.

Claims (4)

1. A method of treating an inflammatory autoimmune disease characterized by an influx of immune cells into the central nervous system, the method consisting essentially of administering to a subject in need thereof, a therapeutically effective amount of a leukotoxin comprising SEQ ID NO: 1, wherein the inflammatory autoimmune disease is multiple sclerosis which is characterized by upregulated expression of leukocyte function antigen-1 (LFA-1) on the surface of activated immune cells from blood and cerebrospinal fluid of the subject, wherein the leukotoxin depletes and/or blocks the activated immune cells in the central nervous system of the subject.

2. The method of claim 1 , wherein the leukotoxin is prepared from Aggregatibacter actinomycetemcomitans.

3. A method of treating an inflammatory autoimmune disease characterized by an influx of immune cells into the central nervous system, the method consisting of administering to a subject in need thereof a therapeutically effective amount of a leukotoxin comprising SEQ ID NO: 1, wherein the inflammatory autoimmune disease is multiple sclerosis which is characterized by upregulated expression of leukocyte function antigen-1 (LFA-1) on the surface of activated immune cells from blood and cerebrospinal fluid of the subject, wherein the leukotoxin depletes and/or blocks the activated immune cells in the central nervous system of the subject.

4. The method of claim 2 , wherein the leukotoxin is prepared from Aggregatibacter actinomycetemcomitans.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2024
From: ACTINOBAC BIOMED, INC.
To: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Reel/Frame 067213/0348 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 28, 2018
From: BELINKA, BENJAMIN
To: ACTINOBAC BIOMED, INC.
Reel/Frame 047604/0602 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 28, 2018
From: KACHLANY, SCOTT
To: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Reel/Frame 047604/0706 →
Continuity (9)
Division 15080089 · Mar 24, 2016
Division 14563421 · Dec 15, 2014
Division 13446949 · Apr 13, 2012
Continuation In Part PCTUS2010056864 · Nov 16, 2010
Continuation In Part PCTUS2010052453 · Oct 13, 2010
Provisional Application 61261984 · Nov 17, 2009
Provisional Application 61285378 · Dec 10, 2009
Provisional Application 61251171 · Oct 13, 2009
Related Publication 20180104305A1 · Apr 19, 2018